Compare Cipla with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 23.6 21.8 108.1% View Chart
P/BV x 2.4 3.3 73.8% View Chart
Dividend Yield % 0.7 0.7 92.1%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-19
DR. REDDYS LAB
Mar-19
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6782,875 23.6%   
Low Rs4841,888 25.6%   
Sales per share (Unadj.) Rs198.2930.2 21.3%  
Earnings per share (Unadj.) Rs18.5117.4 15.8%  
Cash flow per share (Unadj.) Rs35.0185.8 18.8%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.50.8 61.5%  
Book value per share (Unadj.) Rs186.3844.4 22.1%  
Shares outstanding (eoy) m805.70166.07 485.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.92.6 114.5%   
Avg P/E ratio x31.420.3 154.6%  
P/CF ratio (eoy) x16.612.8 129.5%  
Price / Book Value ratio x3.12.8 110.5%  
Dividend payout %16.217.0 95.1%   
Avg Mkt Cap Rs m468,031395,496 118.3%   
No. of employees `00022.622.0 103.1%   
Total wages/salary Rs m28,56533,562 85.1%   
Avg. sales/employee Rs Th7,053.17,032.8 100.3%   
Avg. wages/employee Rs Th1,261.51,527.9 82.6%   
Avg. net profit/employee Rs Th659.1887.7 74.2%   
INCOME DATA
Net Sales Rs m159,710154,482 103.4%  
Other income Rs m4,7663,375 141.2%   
Total revenues Rs m164,475157,857 104.2%   
Gross profit Rs m30,97331,782 97.5%  
Depreciation Rs m13,26311,348 116.9%   
Interest Rs m1,684889 189.5%   
Profit before tax Rs m20,79122,920 90.7%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6953,858 147.6%   
Profit after tax Rs m14,92419,500 76.5%  
Gross profit margin %19.420.6 94.3%  
Effective tax rate %27.416.8 162.7%   
Net profit margin %9.312.6 74.0%  
BALANCE SHEET DATA
Current assets Rs m124,266111,101 111.8%   
Current liabilities Rs m37,71558,973 64.0%   
Net working cap to sales %54.233.7 160.6%  
Current ratio x3.31.9 174.9%  
Inventory Days Days9179 114.2%  
Debtors Days Days9594 100.7%  
Net fixed assets Rs m105,190101,245 103.9%   
Share capital Rs m1,611830 194.1%   
"Free" reserves Rs m148,511139,406 106.5%   
Net worth Rs m150,123140,236 107.1%   
Long term debt Rs m38,30122,000 174.1%   
Total assets Rs m239,633224,656 106.7%  
Interest coverage x13.326.8 49.8%   
Debt to equity ratio x0.30.2 162.6%  
Sales to assets ratio x0.70.7 96.9%   
Return on assets %6.99.1 76.4%  
Return on equity %9.913.9 71.5%  
Return on capital %11.814.9 79.2%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41088,673 64.7%   
Fx outflow Rs m19,04119,104 99.7%   
Net fx Rs m38,36869,569 55.2%   
CASH FLOW
From Operations Rs m16,91128,704 58.9%  
From Investments Rs m-16,687-7,727 216.0%  
From Financial Activity Rs m-3,487-21,326 16.4%  
Net Cashflow Rs m-3,451-314 1,099.1%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 23, 2019 02:55 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS